cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5441/001/1.vr276ns3/2
title: Antarctic blue whales east Antarctic sector of the Southern Ocean-reference-data

description: Andrews-Goff V, Double M. 2022. Deployment details for satellite tags deployed on Antarctic blue whales during the Antarctic blue whale voyage 2013, Ver. 2. Australian Antarctic Data Centre. doi:10.26179/jd0n-va59
description: One aim of the Antarctic blue whale voyage was to attempt to deploy satellite tags on Antarctic blue whales in order to describe their movement and behaviour. This was the first time satellite tags had ever been deployed on Antarctic blue whales. Antarctic blue whale movement has been described using static location information such as that derived from the retrieval of a discovery-tagged whales, photo identification or acoustic data. These techniques however are unable to provide a continuous record of actual movements instead inferring movement from two (or more) known locations at two (or more) separate points in time. Actual movements of the whale between these points in time are not known. As such, detailed information such as large scale migratory movement between breeding and feeding grounds or even fine scale movement within a feeding ground remain poorly understood.
DOI: 10.5441/001/1.vr276ns3/3
title: BDJ_ssm_2h_mpm

description: Andrews-Goff V, Double M. 2022. Deployment details for satellite tags deployed on Antarctic blue whales during the Antarctic blue whale voyage 2013, Ver. 2. Australian Antarctic Data Centre. doi:10.26179/jd0n-va59
description: One aim of the Antarctic blue whale voyage was to attempt to deploy satellite tags on Antarctic blue whales in order to describe their movement and behaviour. This was the first time satellite tags had ever been deployed on Antarctic blue whales. Antarctic blue whale movement has been described using static location information such as that derived from the retrieval of a discovery-tagged whales, photo identification or acoustic data. These techniques however are unable to provide a continuous record of actual movements instead inferring movement from two (or more) known locations at two (or more) separate points in time. Actual movements of the whale between these points in time are not known. As such, detailed information such as large scale migratory movement between breeding and feeding grounds or even fine scale movement within a feeding ground remain poorly understood.
DOI: 10.34740/kaggle/dsv/4463929
title: Elon Musk Tweets
DOI: 10.25375/uct.14873166
title: Umoya omuhle: Infection prevention and control for drug-resistant tuberculosis in South Africa in the era of decentralised care: A whole systems approach. Research questions 3 and 4_KwaZulu Natal.

description: Umoya omuhle is a three-year study that began in 2017 and uses a whole systems approach to look at infection prevention and control for drug-resistant tuberculosis in clinical settings of South Africa in an era of decentralised care. The name, Umoya omuhle, means good air in Zulu, and embodies the project vision of bringing a ‘breath of fresh air' to current thinking on infection prevention and control.
DOI: 10.25375/uct.14873166.v1
title: Umoya omuhle: Infection prevention and control for drug-resistant tuberculosis in South Africa in the era of decentralised care: A whole systems approach. Research questions 3 and 4_KwaZulu Natal.

description: Umoya omuhle is a three-year study that began in 2017 and uses a whole systems approach to look at infection prevention and control for drug-resistant tuberculosis in clinical settings of South Africa in an era of decentralised care. The name, Umoya omuhle, means good air in Zulu, and embodies the project vision of bringing a ‘breath of fresh air' to current thinking on infection prevention and control.
DOI: 10.5517/ccdc.csd.cc1zs0nf
title: CCDC 1840335: Experimental Crystal Structure Determination

description: Related Article: Jongbok Lee, Shi Li, Xiaozhou Ji, Sai Che, Yirui Cao, Daniel P. Tabor, Lei Fang|2022|Mater. Chem. Front.|6|3329|doi:10.1039/D2QM00789D
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc1zs0pg
title: CCDC 1840336: Experimental Crystal Structure Determination

description: Related Article: Jongbok Lee, Shi Li, Xiaozhou Ji, Sai Che, Yirui Cao, Daniel P. Tabor, Lei Fang|2022|Mater. Chem. Front.|6|3329|doi:10.1039/D2QM00789D
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc1zs0rj
title: CCDC 1840338: Experimental Crystal Structure Determination

description: Related Article: Jongbok Lee, Shi Li, Xiaozhou Ji, Sai Che, Yirui Cao, Daniel P. Tabor, Lei Fang|2022|Mater. Chem. Front.|6|3329|doi:10.1039/D2QM00789D
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc1zs0sk
title: CCDC 1840339: Experimental Crystal Structure Determination

description: Related Article: Jongbok Lee, Shi Li, Xiaozhou Ji, Sai Che, Yirui Cao, Daniel P. Tabor, Lei Fang|2022|Mater. Chem. Front.|6|3329|doi:10.1039/D2QM00789D
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2bpv74
title: CCDC 2165946: Experimental Crystal Structure Determination

description: Related Article: Yan Yang, Xu-Yong Chen, Xin-Mei Li, Fang Zhao, Xiang-Tian Bai, Li-Hui Cao|2022|Mater. Chem. Front.|6|3402|doi:10.1039/D2QM00656A
description: Related Article: Yan Yang|2022|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2ckdq2
title: CCDC 2191474: Experimental Crystal Structure Determination

description: Related Article: Elavarasan Pavithra, Sathananthan Kannadasan, Ponnusamy Shanmugam|2022|RSC Advances|12|30712|doi:10.1039/D2RA05849A
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.6084/m9.figshare.21507798.v1
title: Timeseries and wind data

description: This file contains ambient timeseries of calibration and uncalibrated ions measured using ammonium adduct chemical ionization in wintertime New York City, and the corresponding wind data.
DOI: 10.48329/568x-p626
title: CPRD GOLD November 2022

description: The CPRD GOLD database contains longitudinal routinely-collected electronic health records (EHR data) from UK primary care practices using Vision® general practice patient management software. The database captures information on demographic characteristics; diagnoses and symptoms; drug exposures; vaccination history; laboratory tests; and referrals to hospital and specialist care. Access to anonymised data from CPRD is subject to a full licence agreement containing detailed terms and conditions of use. Anonymised patient datasets can be extracted for researchers against specific study specifications, following protocol approval. Further information is available at https://www.cprd.com/data-access.
DOI: 10.3886/e178882
title: Code for: "Facts and Fantasies about Wage Setting and Collective Bargaining"

description: In this article, we document and discuss salient features of collective bargaining systems in the OECD countries, with the goal of debunking some misconceptions and myths and revitalizing the general interest in wage setting and collective bargaining. We hope that such an interest may help close the gap between how economists tend to model wage setting and how wages are actually set. Canonical models of competitive labor markets, monopsony, and search and matching all assume a decentralized wage setting where individual firms and workers determine wages. In most advanced economies, however, it is common that firms or employer associations bargain with unions over wages, producing collective bargaining systems. We show that the characteristics of these systems vary in important ways across advanced economies, with regards to both the scope and the structure of collective bargaining.<br>
DOI: 10.3886/e178882v1
title: Code for: "Facts and Fantasies about Wage Setting and Collective Bargaining"

description: In this article, we document and discuss salient features of collective bargaining systems in the OECD countries, with the goal of debunking some misconceptions and myths and revitalizing the general interest in wage setting and collective bargaining. We hope that such an interest may help close the gap between how economists tend to model wage setting and how wages are actually set. Canonical models of competitive labor markets, monopsony, and search and matching all assume a decentralized wage setting where individual firms and workers determine wages. In most advanced economies, however, it is common that firms or employer associations bargain with unions over wages, producing collective bargaining systems. We show that the characteristics of these systems vary in important ways across advanced economies, with regards to both the scope and the structure of collective bargaining.<br>
DOI: 10.25934/pr00007402.5
title: Available IPD datapackage for study 'A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer'

description: This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study was designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin plus (+) etoposide compared with treatment with placebo + carboplatin + etoposide in chemotherapy-naive participants with ES-SCLC. Participants will be randomized in a 1:1 ratio to receive either atezolizumab + carboplatin + etoposide or placebo + carboplatin + etoposide on 21-day cycles for four cycles in the induction phase followed by maintenance with atezolizumab or placebo until progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Treatment can be continued until persistent radiographic PD or symptomatic deterioration.
DOI: 10.5522/04/16592966.v1
title: A three-wave network analysis of COVID-19's impact on schizotypal traits, paranoia and mental health through loneliness

description: <b>Background </b>The 2019 coronavirus (COVID-19) pandemic has impacted people’s mental wellbeing. Studies to date have examined the prevalence of mental health symptoms (anxiety, depression, loneliness), yet fewer longitudinal studies have compared across background factors and other psychological variables to identify vulnerable sub-groups. This study tests to what extent higher levels of psychotic-like experiences – indexed by schizotypal traits and paranoia – are associated with various mental health variables 6- and 12-months since April 2020.<b> </b><b>Methods </b>Over 2,300 adult volunteers (18-89 years, female=74.9%) with access to the study link online were recruited from the UK, USA, Greece, and Italy. Self-reported levels of schizotypy, paranoia, anxiety, depression, aggression, loneliness, and stress from three timepoints (17 April to 13 July 2020, <i>N<sub>1 </sub></i>=1,599; 17 October to 31 January 2021, <i>N<sub>2 </sub></i>=774; and 17 April to 31 July 2021, <i>N<sub>3 </sub></i>=586) were mapped using network analysis and compared across time and background variables (sex, age, income, country).<b> </b><b>Results </b>Schizotypal traits and paranoia were positively associated with poorer mental health through loneliness, with no effect of age, sex, income levels, countries, and timepoints. Loneliness was the most influential variable across all networks, despite overall reductions in levels of loneliness, schizotypy, paranoia, and aggression during the easing of lockdown. Individuals with higher levels of schizotypal traits/paranoia reported poorer mental health outcomes than individuals in the low-trait groups.<br><b>Conclusion </b>Schizotypal traits and paranoia are associated with poor mental health outcomes through self-perceived loneliness, suggesting that increasing social/community cohesion may improve individuals’ mental wellbeing in the long run.<b> </b><b>Keywords</b>: Network Analysis; Schizotypy; Anxiety; Depression; Stress; Loneliness; Sleep; COVID-19; Longitudinal; Mental Health.
DOI: 10.5522/04/16592966
title: A three-wave network analysis of COVID-19's impact on schizotypal traits, paranoia and mental health through loneliness

description: <b>Background </b>The 2019 coronavirus (COVID-19) pandemic has impacted people’s mental wellbeing. Studies to date have examined the prevalence of mental health symptoms (anxiety, depression, loneliness), yet fewer longitudinal studies have compared across background factors and other psychological variables to identify vulnerable sub-groups. This study tests to what extent higher levels of psychotic-like experiences – indexed by schizotypal traits and paranoia – are associated with various mental health variables 6- and 12-months since April 2020.<b> </b><b>Methods </b>Over 2,300 adult volunteers (18-89 years, female=74.9%) with access to the study link online were recruited from the UK, USA, Greece, and Italy. Self-reported levels of schizotypy, paranoia, anxiety, depression, aggression, loneliness, and stress from three timepoints (17 April to 13 July 2020, <i>N<sub>1 </sub></i>=1,599; 17 October to 31 January 2021, <i>N<sub>2 </sub></i>=774; and 17 April to 31 July 2021, <i>N<sub>3 </sub></i>=586) were mapped using network analysis and compared across time and background variables (sex, age, income, country).<b> </b><b>Results </b>Schizotypal traits and paranoia were positively associated with poorer mental health through loneliness, with no effect of age, sex, income levels, countries, and timepoints. Loneliness was the most influential variable across all networks, despite overall reductions in levels of loneliness, schizotypy, paranoia, and aggression during the easing of lockdown. Individuals with higher levels of schizotypal traits/paranoia reported poorer mental health outcomes than individuals in the low-trait groups.<br><b>Conclusion </b>Schizotypal traits and paranoia are associated with poor mental health outcomes through self-perceived loneliness, suggesting that increasing social/community cohesion may improve individuals’ mental wellbeing in the long run.<b> </b><b>Keywords</b>: Network Analysis; Schizotypy; Anxiety; Depression; Stress; Loneliness; Sleep; COVID-19; Longitudinal; Mental Health.
DOI: 10.25934/pr00006052.9
title: Available IPD datapackage for study 'A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer'

description: This randomized Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+nab-paclitaxel compared with treatment with carboplatin+nab-paclitaxel in chemotherapy-naive participants with Stage IV non-squamous NSCLC. Participants will be randomized in a 2:1 ratio to Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) or Arm B (Nab-Paclitaxel+Carboplatin).
DOI: 10.25934/pr00006051.13
title: Available IPD datapackage for study 'A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer'

description: This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared with treatment with carboplatin+paclitaxel+bevacizumab in chemotherapy-naïve participants with Stage IV non-squamous NSCLC. Participants will be randomized in a 1:1:1 ratio to Arm A (Atezolizumab+Carboplatin+Paclitaxel), Arm B (Atezolizumab+Carboplatin+Paclitaxel+Bevacizumab), or Arm C (Carboplatin+Paclitaxel+Bevacizumab).
DOI: 10.25934/pr00005998.2
title: Available IPD datapackage for study 'A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer'

description: This three-cohort, multi-stage, randomized, Phase II, multicenter trial will evaluate the safety and tolerability and estimate the efficacy of cobimetinib plus paclitaxel versus placebo plus paclitaxel in Cohort I, of cobimetinib plus atezolizumab plus paclitaxel in Cohort II, and of cobimetinib plus atezolizumab plus nab-paclitaxel in Cohort III in participants with metastatic or locally advanced, triple-negative adenocarcinoma of the breast who have not received prior systemic therapy for metastatic breast cancer (MBC). Participants may continue on study treatment until the development of progressive disease (PD) or the loss of clinical benefit, unacceptable toxicity, and/or consent withdrawal. The Cohort I target sample size is 12 participants for the safety run-in stage and approximately 90 participants in the expansion stage. Each of Cohorts II and III will consist of a safety run-in stage of approximately 15 participants followed by an expansion stage of approximately 15 participants.
DOI: 10.5281/zenodo.7299381
title: Turbidity shapes shallow Southwestern Atlantic benthic reef communities

description: Southwestern Atlantic reefs (Brazilian Province) occur along a broad latitudinal range (~5°N-27°S) and under varied environmental conditions. We provide here the database (reef benthic coverage) used by Santana et al. "Turbidity shapes shallow Southwestern Atlantic benthic reef communities" (Marine Environmental Research, in press). The data encompasses the four Brazilian oceanic islands and the coast (139 sites distributed between 0°55’N - 27°00’S) and is composed by a combination of location and depth.
DOI: 10.5281/zenodo.7299380
title: Turbidity shapes shallow Southwestern Atlantic benthic reef communities

description: Southwestern Atlantic reefs (Brazilian Province) occur along a broad latitudinal range (~5°N-27°S) and under varied environmental conditions. We provide here the database (reef benthic coverage) used by Santana et al. "Turbidity shapes shallow Southwestern Atlantic benthic reef communities" (Marine Environmental Research, in press). The data encompasses the four Brazilian oceanic islands and the coast (139 sites distributed between 0°55’N - 27°00’S) and is composed by a combination of location and depth.
DOI: 10.6084/m9.figshare.21511206
title: fds_kombiniert.csv

description: Data for study on frustration tolerance among Computer-Science-related students in CS1
DOI: 10.6084/m9.figshare.21511206.v1
title: fds_kombiniert.csv

description: Data for study on frustration tolerance among Computer-Science-related students in CS1
DOI: 10.25934/pr00005598.8
title: Available IPD datapackage for study 'A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy'

description: This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen. The anticipated time on study treatment is based on continued clinical benefit, i.e., until disease progression or unacceptable toxicity. The target sample size is 931 participants.
DOI: 10.25934/pr00005796.7
title: Available IPD datapackage for study 'A Phase II, Multicenter, Single-Arm Study OF Atezolizumab In Patients With PD-L1-Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer'

description: This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Participants will receive Atezolizumab 1200 milligrams (mg) intravenously every 3 weeks as long as participants are experiencing clinical benefit as assessed by the investigator, that is , in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.
DOI: 10.25934/pr00005794.17
title: Available IPD datapackage for study 'A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy'

description: This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death−ligand 1 [anti-PD-L1] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Participants were randomized 1:1 to receive either docetaxel or atezolizumab. Treatment may continue as long as participants experienced clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.
DOI: 10.25934/pr00005599.6
title: Available IPD datapackage for study 'A Phase II, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Administered as Monotherapy or in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma'

description: This multicenter, randomized, open-label study will evaluate the efficacy, safety and tolerability of atezolizumab as monotherapy or in combination with bevacizumab versus sunitinib in participants with histologically confirmed, inoperable, locally advanced or metastatic renal cell carcinoma who have not received prior systemic therapy either in the adjuvant or metastatic setting.